Alternative Data for Adaptive Biotechnologies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 14 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 31,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 2,340 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,212 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,296 | Sign up | Sign up | Sign up |
| X Followers | 4,541 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 46 | Sign up | Sign up | Sign up |
| Linkedin Employees | 650 | Sign up | Sign up | Sign up |
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
| Price | $13.40 |
| Target Price | Sign up |
| Volume | 1,740,008 |
| Market Cap | $2.29B |
| Year Range | $10.33 - $20.46 |
| Dividend Yield | 0% |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?February 28 - Yahoo Entertainment |
JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $21February 6 - Benzinga |
|
Adaptive Biotechnologies shares are trading lower. The company reported Q4 financial results.February 5 - Benzinga |
|
 |
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call TranscriptFebruary 5 - SeekingAlpha |
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22February 5 - Benzinga |
|
Adaptive Biotechnologies Corporation 2025 Q4 - Results - Earnings Call PresentationFebruary 5 - SeekingAlpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 72M | 18M | 53M | -14M | -6.4M | -0.090 |
| Q3 '25 | 94M | 18M | 76M | 9.5M | 17M | 0.060 |
| Q2 '25 | 59M | 18M | 41M | -26M | -18M | -0.170 |
| Q1 '25 | 52M | 17M | 35M | -30M | -30M | -0.200 |
| Q4 '24 | 47M | 18M | 29M | -34M | -26M | -0.230 |
Insider Transactions View All
| RUBINSTEIN JULIE filed to sell 434,188 shares at $15.5. April 8 '26 |
| ROBINS CHAD M filed to sell 2,180,518 shares at $15.2. April 8 '26 |
| RUBINSTEIN JULIE filed to sell 434,288 shares at $14.8. April 8 '26 |
| RUBINSTEIN JULIE filed to sell 438,526 shares at $13.6. April 8 '26 |
| ROBINS CHAD M filed to sell 2,217,781 shares at $14.4. April 8 '26 |
Similar companies
Read more about Adaptive Biotechnologies (ADPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Adaptive Biotechnologies
The Market Cap of Adaptive Biotechnologies is $2.29B.
Currently, the price of one share of Adaptive Biotechnologies stock is $13.40.
The ADPT stock price chart above provides a comprehensive visual representation of Adaptive Biotechnologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptive Biotechnologies shares. Our platform offers an up-to-date ADPT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Adaptive Biotechnologies (ADPT) does not offer dividends to its shareholders. Investors interested in Adaptive Biotechnologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Adaptive Biotechnologies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
